151 related articles for article (PubMed ID: 15692846)
21. Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine.
Lim SY; Laxmanan S; Stuart G; Ghosh SK
Cancer Detect Prev; 2001; 25(5):470-8. PubMed ID: 11718453
[TBL] [Abstract][Full Text] [Related]
22. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour.
Dyke RJ; McBride H; George AJ; Hamblin TJ; Stevenson FK
Cell Immunol; 1991 Jan; 132(1):70-83. PubMed ID: 2065360
[TBL] [Abstract][Full Text] [Related]
23. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
24. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. III. MHC class I-restricted CTL recognizes the processed form(s) of idiotype.
Chakrabarti D; Ghosh SK
Cell Immunol; 1992 Oct; 144(2):455-64. PubMed ID: 1394454
[TBL] [Abstract][Full Text] [Related]
25. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas.
Timmerman JM; Caspar CB; Lambert SL; Syrengelas AD; Levy R
Blood; 2001 Mar; 97(5):1370-7. PubMed ID: 11222382
[TBL] [Abstract][Full Text] [Related]
26. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
Gravelle M; Ochi A
J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
[TBL] [Abstract][Full Text] [Related]
27. H-2-linked Ir gene control of VH determinant(s)-specific helper T cells.
Kawahara DJ; Marrack P; Kappler JW
J Mol Cell Immunol; 1986; 2(5):255-64. PubMed ID: 2978232
[TBL] [Abstract][Full Text] [Related]
28. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
[TBL] [Abstract][Full Text] [Related]
29. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
Tamura GS; McGrath MS; Weissman IL
J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
[TBL] [Abstract][Full Text] [Related]
30. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice.
Cohen S; Haimovich J; Hollander N
J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602
[TBL] [Abstract][Full Text] [Related]
31. Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination.
Cesco-Gaspere M; Zentilin L; Giacca M; Burrone OR
Scand J Immunol; 2008 Jul; 68(1):58-66. PubMed ID: 18482206
[TBL] [Abstract][Full Text] [Related]
32. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines.
Hawkins RE; Zhu D; Ovecka M; Winter G; Hamblin TJ; Long A; Stevenson FK
Blood; 1994 Jun; 83(11):3279-88. PubMed ID: 8193363
[TBL] [Abstract][Full Text] [Related]
33. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
[TBL] [Abstract][Full Text] [Related]
34. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
35. Different properties of T-cell epitopes within complementarity-determining regions 1 and 2 of idiotypic VH in B-lymphoma.
Wen YJ; Lim SH
Scand J Immunol; 1999 Sep; 50(3):296-301. PubMed ID: 10447939
[TBL] [Abstract][Full Text] [Related]
36. Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.
Morecki S; Levi S; Puyesky Y; Slavin S
Cancer Immunol Immunother; 1995 Oct; 41(4):236-42. PubMed ID: 7489566
[TBL] [Abstract][Full Text] [Related]
37. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
George AJ; Tutt AL; Stevenson FK
J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
Illidge T; Honeychurch J; Vandersteen A; Cragg M
Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
[TBL] [Abstract][Full Text] [Related]
39. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
40. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established.
Vitetta ES; Tucker TF; Racila E; Huang YW; Marches R; Lane N; Scheuermann RH; Street NE; Watanabe T; Uhr JW
Blood; 1997 Jun; 89(12):4425-36. PubMed ID: 9192767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
